Company Name,Company Description,Logo Path,Original Link,Country,Founded,Industry,Sector,Employees,CEO,Address,Phone,Website,Ticker Symbol,Exchange,Fiscal Year,Reporting Currency,CIK Code,CUSIP Number,ISIN Number,SIC Code,IPO Date,Stock Type,Employer ID,IPO Price,Share Class
Haleon plc,"Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.
The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.",Data/company_logos_stock_analysis\Haleon_plc_logo.svg,https://stockanalysis.com/stocks/hln/,United Kingdom,2022,Drug Manufacturers - Specialty & Generic,Healthcare,"25,408",Brian McNamara,"The Heights, Building 5, First Floor
Weybridge, KT13 0NY
United Kingdom",44 1932 822000,haleon.com,HLN,NYSE,January - December,GBP,0001900304,405552100,US4055521003,2844,,,,,
Teva Pharmaceutical Industries Limited,"Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM.
In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.
The company was founded in 1901 and is based in Tel Aviv, Israel.",Data/company_logos_stock_analysis\Teva_Pharmaceutical_Industries_Limited_logo.svg,https://stockanalysis.com/stocks/teva/,Israel,1901,Drug Manufacturers - Specialty & Generic,Healthcare,"37,851",Richard Francis,"124 Dvora HaNevi’a Street
Tel Aviv, 6944020
Israel",972 3 914 8213,tevapharm.com,TEVA,NYSE,January - December,USD,0000818686,881624209,US8816242098,2834,,,,,
Zoetis Inc.,"Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.
In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.
It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.
Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.",Data/company_logos_stock_analysis\Zoetis_Inc._logo.svg,https://stockanalysis.com/stocks/zts/,United States,1952,Drug Manufacturers - Specialty & Generic,Healthcare,"14,100",Kristin Peck,"10 Sylvan Way
Parsippany, New Jersey 07054
United States",973 822 7000,zoetis.com,ZTS,NYSE,January - December,USD,0001555280,98978V103,US98978V1035,2834,"Feb 1, 2013",Common Stock,46-0696167,,
"BeiGene, Ltd.","BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.
The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK‑targeting chimeric degradation activation compound active against wild‑type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.","Data/company_logos_stock_analysis\BeiGene,_Ltd._logo.svg",https://stockanalysis.com/stocks/onc/,Cayman Islands,2010,Biotechnology,Healthcare,"10,600",John Oyler,"94 Solaris Avenue
Camana Bay, KY1-1108
Cayman Islands",345-949-4123,beigene.com,ONC,NASDAQ,January - December,CNY,0001651308,,,2834,,,98-1209416,,
argenx SE,"argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH.
It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services.
argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.",Data/company_logos_stock_analysis\argenx_SE_logo.svg,https://stockanalysis.com/stocks/argx/,Netherlands,2008,Biotechnology,Healthcare,"1,148",Timothy Van Hauwermeiren,"Laarderhoogtweg 25
Amsterdam, 1101EB
Netherlands",31 10 703 8441,argenx.com,ARGX,NASDAQ,January - December,USD,0001697862,04016X101,NL0010832176,2836,"May 18, 2017",,,,
Takeda Pharmaceutical Company Limited,"Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr.
Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr.
Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences.
The company was founded in 1781 and is headquartered in Tokyo, Japan.",Data/company_logos_stock_analysis\Takeda_Pharmaceutical_Company_Limited_logo.svg,https://stockanalysis.com/stocks/tak/,Japan,1781,Drug Manufacturers - Specialty & Generic,Healthcare,"49,281",Christophe Weber,"1-1, Nihonbashi-Honcho 2-chome, Chuo-ku
Tokyo, 103-8668
Japan",81 3 3278-2111,takeda.com,TAK,NYSE,April - March,JPY,0001395064,874060205,US8740602052,2834,,,,,
"Regeneron Pharmaceuticals, Inc.","Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","Data/company_logos_stock_analysis\Regeneron_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/regn/,United States,1988,Biotechnology,Healthcare,"13,450",Leonard Schleifer,"777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
United States",914 847 7000,regeneron.com,REGN,NASDAQ,January - December,USD,0000872589,75886F107,US75886F1075,2834,"Apr 2, 1991",Common Stock,13-3444607,,
BioNTech SE,"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.
It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases.
It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa’s mrna vaccine ecosystem.
BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.",Data/company_logos_stock_analysis\BioNTech_SE_logo.svg,https://stockanalysis.com/stocks/bntx/,Germany,2008,Biotechnology,Healthcare,"6,133",Ugur Sahin,"An der Goldgrube 12
Mainz, 55131
Germany",49 6131 9084 0,biontech.de,BNTX,NASDAQ,January - December,EUR,0001776985,09075V102,US09075V1026,2836,"Oct 10, 2019",,,$15.00,
"Alnylam Pharmaceuticals, Inc.","Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial.
Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran.
It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Alnylam_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/alny/,United States,2002,Biotechnology,Healthcare,"2,100",Yvonne Greenstreet,"675 West Kendall Street, Henri A. Termeer Square
Cambridge, Massachusetts 02142
United States",617 551 8200,alnylam.com,ALNY,NASDAQ,January - December,USD,0001178670,02043Q107,US02043Q1076,2834,"May 28, 2004",Common Stock,77-0602661,,
Vertex Pharmaceuticals Incorporated,"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial.
Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.
Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy.
Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.",Data/company_logos_stock_analysis\Vertex_Pharmaceuticals_Incorporated_logo.svg,https://stockanalysis.com/stocks/vrtx/,United States,1989,Biotechnology,Healthcare,"5,400",Reshma Kewalramani,"50 Northern Avenue
Boston, Massachusetts 02210
United States",617 341 6100,vrtx.com,VRTX,NASDAQ,January - December,USD,0000875320,92532F100,US92532F1003,2834,"Jul 24, 1991",,04-3039129,,
Royalty Pharma plc,"Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies.
In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes.
The company was founded in 1996 and is based in New York, New York.",Data/company_logos_stock_analysis\Royalty_Pharma_plc_logo.svg,https://stockanalysis.com/stocks/rprx/,United States,1996,Biotechnology,Healthcare,89,Pablo Legorreta,"110 East 59th Street
New York, New York 10022
United States",212 883 0200,royaltypharma.com,RPRX,NASDAQ,January - December,USD,0001802768,G7709Q104,GB00BMVP7Y09,2834,"Jun 16, 2020",,,$28.00,Class A Shares
United Therapeutics Corporation,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.
It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.",Data/company_logos_stock_analysis\United_Therapeutics_Corporation_logo.svg,https://stockanalysis.com/stocks/uthr/,United States,1996,Biotechnology,Healthcare,"1,168",Martine Rothblatt,"1000 Spring Street
Silver Spring, Maryland 20910
United States",301 608 9292,unither.com,UTHR,NASDAQ,January - December,USD,0001082554,91307C102,US91307C1027,2834,"Jun 17, 1999",,52-1984749,,
"Moderna, Inc.","Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Moderna,_Inc._logo.svg",https://stockanalysis.com/stocks/mrna/,United States,2010,Biotechnology,Healthcare,"5,600",Stephane Bancel,"200 Technology Square
Cambridge, Massachusetts 02139
United States",617 714 6500,modernatx.com,MRNA,NASDAQ,January - December,USD,0001682852,60770K107,US60770K1079,2836,"Dec 7, 2018",Common Stock,81-3467528,,
"Neurocrine Biosciences, Inc.","Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Neurocrine_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/nbix/,United States,1992,Drug Manufacturers - Specialty & Generic,Healthcare,"1,400",Kyle Gano,"12780 El Camino Real
San Diego, California 92130
United States",858 617 7600,neurocrine.com,NBIX,NASDAQ,January - December,USD,0000914475,64125C109,US64125C1099,2836,"May 23, 1996",Common Stock,33-0525145,,
Incyte Corporation,"Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.
The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460.
It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib.
The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers.
The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.",Data/company_logos_stock_analysis\Incyte_Corporation_logo.svg,https://stockanalysis.com/stocks/incy/,United States,1991,Biotechnology,Healthcare,"2,524",Herve Hoppenot,"1801 Augustine Cut-Off
Wilmington, Delaware 19803
United States",302 498 6700,incyte.com,INCY,NASDAQ,January - December,USD,0000879169,45337C102,US45337C1027,8731,"Nov 4, 1993",,94-3136539,,
Genmab A/S,"Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.
It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.
It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S.
Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",,https://stockanalysis.com/stocks/gmab/,Denmark,1999,Biotechnology,Healthcare,"2,204",Jan G.J. de Winkel,"Carl Jacobsens Vej 30, Valby
Copenhagen, 2500
Denmark",45 70 20 27 28,genmab.com,GMAB,NASDAQ,January - December,DKK,0001434265,372303206,US3723032062,2834,,,,,
Summit Therapeutics Inc.,"Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab.
The company was founded in 2003 and is headquartered in Miami, Florida.",Data/company_logos_stock_analysis\Summit_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/smmt/,United States,2003,Biotechnology,Healthcare,105,Robert W. Duggan,"601 Brickell Key Drive, Suite 1000
Miami, Florida 33131
United States",650 460 8308,summittxinc.com,SMMT,NASDAQ,January - December,USD,0001599298,86627T108,US86627T1088,2834,,,37-1979717,,
Viatris Inc.,"Viatris Inc. operates as a healthcare company worldwide.
The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.
It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.
It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names.
The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.",Data/company_logos_stock_analysis\Viatris_Inc._logo.svg,https://stockanalysis.com/stocks/vtrs/,United States,1961,Drug Manufacturers - Specialty & Generic,Healthcare,"38,000",Scott Smith,"1000 Mylan Boulevard
Canonsburg, Pennsylvania 15317
United States",724 514 1800,viatris.com,VTRS,NASDAQ,January - December,USD,0001792044,92556V106,US92556V1061,2834,,Common Stock,83-4364296,,
Dr. Reddy's Laboratories Limited,"Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.
It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments.
The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products.
This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.
The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services.
The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.
Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.",Data/company_logos_stock_analysis\Dr._Reddy's_Laboratories_Limited_logo.svg,https://stockanalysis.com/stocks/rdy/,India,1984,Drug Manufacturers - Specialty & Generic,Healthcare,"27,048",Erez Israeli,"8-2-337, Road No. 3, Banjara Hills
Hyderabad, 500034
India",91 40 4900 2900,drreddys.com,RDY,NYSE,April - March,INR,0001135951,256135203,US2561352038,2834,,,,,
BioMarin Pharmaceutical Inc.,"BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.
Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.
The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.
It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation.
The company was incorporated in 1996 and is headquartered in San Rafael, California.",Data/company_logos_stock_analysis\BioMarin_Pharmaceutical_Inc._logo.svg,https://stockanalysis.com/stocks/bmrn/,United States,1996,Biotechnology,Healthcare,"3,401",Alexander Hardy,"770 Lindaro Street
San Rafael, California 94901
United States",415 506 6700,biomarin.com,BMRN,NASDAQ,January - December,USD,0001048477,09061G101,US09061G1013,2834,"Jul 23, 1999",Common Stock,68-0397820,,
"Sarepta Therapeutics, Inc.","Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio.
The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Sarepta_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/srpt/,United States,1980,Biotechnology,Healthcare,"1,314",Douglas Ingram,"215 First Street, Suite 415
Cambridge, Massachusetts 02142
United States",617 274 4000,sarepta.com,SRPT,NASDAQ,January - December,USD,0000873303,803607100,US8036071004,2834,"Jun 3, 1997",Common Stock,93-0797222,,
Insmed Incorporated,"Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",Data/company_logos_stock_analysis\Insmed_Incorporated_logo.svg,https://stockanalysis.com/stocks/insm/,United States,1988,Biotechnology,Healthcare,912,William Lewis,"700 US Highway 202/206
Bridgewater, New Jersey 08807
United States",908 977 9900,insmed.com,INSM,NASDAQ,January - December,USD,0001104506,457669307,US4576693075,2834,"Jun 1, 2000",Common Stock,54-1972729,,
Bio-Techne Corporation,"Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.
The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease.
The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.",Data/company_logos_stock_analysis\Bio-Techne_Corporation_logo.svg,https://stockanalysis.com/stocks/tech/,United States,1976,Biotechnology,Healthcare,"3,050",Kim Kelderman,"614 McKinley Place N.E.
Minneapolis, Minnesota 55413
United States",612 379 8854,bio-techne.com,TECH,NASDAQ,July - June,USD,0000842023,09073M104,US09073M1045,2836,"Feb 9, 1989",Common Stock,41-1427402,,
"Exelixis, Inc.","Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload.
It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F.
Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V.
and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000.
Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.","Data/company_logos_stock_analysis\Exelixis,_Inc._logo.svg",https://stockanalysis.com/stocks/exel/,United States,1994,Biotechnology,Healthcare,"1,310",Michael Morrissey,"1851 Harbor Bay Parkway
Alameda, California 94502
United States",650 837 7000,exelixis.com,EXEL,NASDAQ,January - December,USD,0000939767,30161Q104,US30161Q1040,2836,"Apr 7, 2000",Common Stock,04-3257395,,
"Vaxcyte, Inc.","Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.
The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.","Data/company_logos_stock_analysis\Vaxcyte,_Inc._logo.svg",https://stockanalysis.com/stocks/pcvx/,United States,2013,Biotechnology,Healthcare,254,Grant Pickering,"825 Industrial Road, Suite 300
San Carlos, California 94070
United States",650 837 0111,vaxcyte.com,PCVX,NASDAQ,January - December,USD,0001649094,92243G108,US92243G1085,2836,"Jun 12, 2020",Common Stock,46-4233385,$16.00,
"Intra-Cellular Therapies, Inc.","Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson’s disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders.
Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.","Data/company_logos_stock_analysis\Intra-Cellular_Therapies,_Inc._logo.svg",https://stockanalysis.com/stocks/itci/,United States,2002,Drug Manufacturers - Specialty & Generic,Healthcare,610,Sharon Mates,"430 East 29th Street
New York, New York 10016
United States",646 440 9333,intracellulartherapies.com,ITCI,NASDAQ,January - December,USD,0001567514,46116X101,US46116X1019,2834,,Common Stock,36-4742850,,
Roivant Sciences Ltd.,"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform.
It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis.
The company was founded in 2014 and is based in London, the United Kingdom.",Data/company_logos_stock_analysis\Roivant_Sciences_Ltd._logo.svg,https://stockanalysis.com/stocks/roiv/,United Kingdom,2014,Biotechnology,Healthcare,908,Matthew Gline,"50 Broadway, 7th Floor
London, SW1H 0DB
United Kingdom",44 20 7400 3347,roivant.com,ROIV,NASDAQ,April - March,USD,0001635088,G76279101,BMG762791017,2834,,,98-1173944,,
Ascendis Pharma A/S,"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.",,https://stockanalysis.com/stocks/asnd/,Denmark,2006,Biotechnology,Healthcare,879,Jan Mikkelsen,"Tuborg Boulevard 12
Hellerup, 2900
Denmark",45 70 22 22 44,ascendispharma.com,ASND,NASDAQ,January - December,EUR,0001612042,04351P101,US04351P1012,2834,"Jan 28, 2015",,,,
"Revolution Medicines, Inc.","Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.
The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial.
Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Revolution_Medicines,_Inc._logo.svg",https://stockanalysis.com/stocks/rvmd/,United States,2014,Biotechnology,Healthcare,378,Mark Goldsmith,"700 Saginaw Drive
Redwood City, California 94063
United States",650 481 6801,revmed.com,RVMD,NASDAQ,January - December,USD,0001628171,76155X100,US76155X1000,2836,"Feb 13, 2020",Common Stock,47-2029180,$17.00,
"Madrigal Pharmaceuticals, Inc.","Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
The company is headquartered in West Conshohocken, Pennsylvania.","Data/company_logos_stock_analysis\Madrigal_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/mdgl/,United States,2011,Biotechnology,Healthcare,376,William Sibold,"Four Tower Bridge, Suite 200
West Conshohocken, Pennsylvania 19428
United States",267 824 2827,madrigalpharma.com,MDGL,NASDAQ,January - December,USD,0001157601,558868105,US5588681057,2834,,Common Stock,,,
Jazz Pharmaceuticals plc,"Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.
The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders.
The company was incorporated in 2003 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Jazz_Pharmaceuticals_plc_logo.svg,https://stockanalysis.com/stocks/jazz/,Ireland,2003,Biotechnology,Healthcare,"2,800",Bruce Cozadd,"Waterloo Exchange, Fifth Floor
Dublin, D04 E5W7
Ireland",353 1 634 7800,jazzpharma.com,JAZZ,NASDAQ,January - December,USD,0001232524,G50871105,IE00B4Q5ZN47,2834,"Jun 1, 2007",Common Stock,98-1032470,,
"Lantheus Holdings, Inc.","Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer.
In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;.
It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC.
The company was founded in 1956 and is based in Bedford, Massachusetts.","Data/company_logos_stock_analysis\Lantheus_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/lnth/,United States,1956,Drug Manufacturers - Specialty & Generic,Healthcare,834,Brian Markison,"201 Burlington Road, South Building
Bedford, Massachusetts 01730
United States",978 671 8001,lantheus.com,LNTH,NASDAQ,January - December,USD,0001521036,516544103,US5165441032,2835,"Jun 25, 2015",Common Stock,35-2318913,,
"Halozyme Therapeutics, Inc.","Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.
In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis.
Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.
Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Halozyme_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/halo/,United States,1998,Biotechnology,Healthcare,373,Helen Torley,"12390 El Camino Real
San Diego, California 92130
United States",858 794 8889,halozyme.com,HALO,NASDAQ,January - December,USD,0001159036,40637H109,US40637H1095,2836,,Common Stock,88-0488686,,
Legend Biotech Corporation,"Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.
The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.",Data/company_logos_stock_analysis\Legend_Biotech_Corporation_logo.svg,https://stockanalysis.com/stocks/legn/,United States,2014,Biotechnology,Healthcare,"1,826",Ying Huang,"2101 Cottontail Lane
Somerset, New Jersey 08873
United States",732 317 5050,legendbiotech.com,LEGN,NASDAQ,January - December,USD,0001801198,52490G102,US52490G1022,2834,"Jun 5, 2020",,,$23.00,
Elanco Animal Health Incorporated,"Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.
It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.
Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.",Data/company_logos_stock_analysis\Elanco_Animal_Health_Incorporated_logo.svg,https://stockanalysis.com/stocks/elan/,United States,1954,Drug Manufacturers - Specialty & Generic,Healthcare,"9,800",Jeffrey Simmons,"2500 Innovation Way
Greenfield, Indiana 46140
United States",877 352 6261,elanco.com,ELAN,NYSE,January - December,USD,0001739104,28414H103,US28414H1032,2834,"Sep 20, 2018",Common Stock,82-5497352,,
Blueprint Medicines Corporation,"Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.
It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.
Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Blueprint_Medicines_Corporation_logo.svg,https://stockanalysis.com/stocks/bpmc/,United States,2008,Biotechnology,Healthcare,655,Kathryn Haviland,"45 Sidney Street
Cambridge, Massachusetts 02139
United States",617 374 7580,blueprintmedicines.com,BPMC,NASDAQ,January - December,USD,0001597264,09627Y109,US09627Y1091,2834,"Apr 30, 2015",Common Stock,,,
"Nuvalent, Inc.","Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.
The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Nuvalent,_Inc._logo.svg",https://stockanalysis.com/stocks/nuvl/,United States,2017,Biotechnology,Healthcare,92,James Porter,"One Broadway, 14th Floor
Cambridge, Massachusetts 02142
United States",857 357 7000,nuvalent.com,NUVL,NASDAQ,January - December,USD,0001861560,670703107,US6707031075,2834,"Jul 29, 2021",Common Stock,,$17.00,Class A Shares
"BridgeBio Pharma, Inc.","BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.","Data/company_logos_stock_analysis\BridgeBio_Pharma,_Inc._logo.svg",https://stockanalysis.com/stocks/bbio/,United States,2015,Biotechnology,Healthcare,556,Neil Kumar,"3160 Porter Drive, Suite 250
Palo Alto, California 94304
United States",650 391 9740,bridgebio.com,BBIO,NASDAQ,January - December,USD,0001743881,10806X102,US10806X1028,2834,"Jun 27, 2019",Common Stock,,$17.00,
"Cytokinetics, Incorporated","Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
It develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
The company’s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\Cytokinetics,_Incorporated_logo.svg",https://stockanalysis.com/stocks/cytk/,United States,1997,Biotechnology,Healthcare,423,Robert Blum,"350 Oyster Point Boulevard
South San Francisco, California 94080
United States",650 624 3000,cytokinetics.com,CYTK,NASDAQ,January - December,USD,0001061983,23282W605,US23282W6057,2834,"Apr 29, 2004",Common Stock,94-3291317,,
"Ionis Pharmaceuticals, Inc.","Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2.
It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics.
The company was incorporated in 1989 and is based in Carlsbad, California.","Data/company_logos_stock_analysis\Ionis_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/ions/,United States,1989,Biotechnology,Healthcare,927,Brett Monia,"2855 Gazelle Court
Carlsbad, California 92010
United States",760 931 9200,ionispharma.com,IONS,NASDAQ,January - December,USD,0000874015,462222100,US4622221004,2834,"May 17, 1991",Common Stock,33-0336973,,
Corcept Therapeutics Incorporated,"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial.
The company was incorporated in 1998 and is headquartered in Menlo Park, California.",Data/company_logos_stock_analysis\Corcept_Therapeutics_Incorporated_logo.svg,https://stockanalysis.com/stocks/cort/,United States,1998,Biotechnology,Healthcare,352,Joseph Belanoff,"149 Commonwealth Drive
Menlo Park, California 94025
United States",650 327 3270,corcept.com,CORT,NASDAQ,January - December,USD,0001088856,218352102,US2183521028,2834,,Common Stock,77-0487658,,
"Krystal Biotech, Inc.","Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States.
It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.","Data/company_logos_stock_analysis\Krystal_Biotech,_Inc._logo.svg",https://stockanalysis.com/stocks/krys/,United States,2015,Biotechnology,Healthcare,229,Krish Krishnan,"2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
United States",412 586 5830,krystalbio.com,KRYS,NASDAQ,January - December,USD,0001711279,501147102,US5011471027,2836,"Sep 20, 2017",Common Stock,82-1080209,,
"ADMA Biologics, Inc.","ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.
pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.
The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","Data/company_logos_stock_analysis\ADMA_Biologics,_Inc._logo.svg",https://stockanalysis.com/stocks/adma/,United States,2004,Biotechnology,Healthcare,624,Adam Grossman,"465 State Route 17
Ramsey, New Jersey 07446
United States",201 478 5552,admabiologics.com,ADMA,NASDAQ,January - December,USD,0001368514,000899104,US0008991046,2836,,Common Stock,56-2590442,,
Alkermes plc,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.
It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Alkermes_plc_logo.svg,https://stockanalysis.com/stocks/alks/,Ireland,1987,Drug Manufacturers - Specialty & Generic,Healthcare,"2,100",Richard Pops,"Connaught House, 1 Burlington Road
Dublin, D04 C5Y6
Ireland",353 1 772 8000,alkermes.com,ALKS,NASDAQ,January - December,USD,0001520262,G01767105,IE00B56GVS15,2834,"Jul 16, 1991",,98-1007018,,
"Viking Therapeutics, Inc.","Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Viking_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/vktx/,United States,2012,Biotechnology,Healthcare,27,Brian Lian,"9920 Pacific Heights Boulevard, Suite 350
San Diego, California 92121
United States",858 704 4660,vikingtherapeutics.com,VKTX,NASDAQ,January - December,USD,0001607678,92686J106,US92686J1060,2834,"Apr 29, 2015",Common Stock,46-1073877,,
Ultragenyx Pharmaceutical Inc.,"Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.
Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.",Data/company_logos_stock_analysis\Ultragenyx_Pharmaceutical_Inc._logo.svg,https://stockanalysis.com/stocks/rare/,United States,2010,Biotechnology,Healthcare,"1,276",Emil Kakkis,"60 Leveroni Court
Novato, California 94949
United States",415 483 8800,ultragenyx.com,RARE,NASDAQ,January - December,USD,0001515673,90400D108,US90400D1081,2834,"Jan 31, 2014",Common Stock,27-2546083,,
Alvotech,"Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product.
Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.",Data/company_logos_stock_analysis\Alvotech_logo.svg,https://stockanalysis.com/stocks/alvo/,Luxembourg,2013,Drug Manufacturers - Specialty & Generic,Healthcare,999,Robert Wessman,"9, Rue de Bitbourg
Luxembourg City, 1273
Luxembourg",,alvotech.com,ALVO,NASDAQ,January - December,USD,0001898416,L01800108,LU2458332611,2836,,,98-1629342,,
"TG Therapeutics, Inc.","TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A.
for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.
TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.","Data/company_logos_stock_analysis\TG_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/tgtx/,United States,1993,Biotechnology,Healthcare,264,Michael Weiss,"3020 Carrington Mill Blvd., Suite 475
Morrisville, North Carolina 27560
United States",212 554 4484,tgtherapeutics.com,TGTX,NASDAQ,January - December,USD,0001001316,88322Q108,US88322Q1085,2834,"Dec 14, 1995",Common Stock,36-3898269,,
"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.
The company was incorporated in 2012 and is based in New York, New York.","Data/company_logos_stock_analysis\Axsome_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/axsm/,United States,2012,Biotechnology,Healthcare,545,Herriot Tabuteau,"One World Trade Center, 22nd Floor
New York, New York 10007
United States",212 332 3241,axsome.com,AXSM,NASDAQ,January - December,USD,0001579428,05464T104,US05464T1043,2834,"Nov 19, 2015",Common Stock,45-4241907,,
Scholar Rock Holding Corporation,"Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Scholar_Rock_Holding_Corporation_logo.svg,https://stockanalysis.com/stocks/srrk/,United States,2012,Biotechnology,Healthcare,150,Jay Backstrom,"301 Binney Street, 3rd Floor
Cambridge, Massachusetts 02142
United States",857 259 3860,scholarrock.com,SRRK,NASDAQ,January - December,USD,0001727196,80706P103,US80706P1030,2836,"May 24, 2018",Common Stock,82-3750435,,
"Crinetics Pharmaceuticals, Inc.","Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity.
Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Crinetics_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/crnx/,United States,2008,Biotechnology,Healthcare,290,R. Struthers,"6055 Lusk Boulevard
San Diego, California 92121
United States",858 450 6464,crinetics.com,CRNX,NASDAQ,January - December,USD,0001658247,22663K107,US22663K1079,2834,"Jul 18, 2018",Common Stock,26-3744114,,
"Arcellx, Inc.","Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
In addition, the company’s preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs.
It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel.
The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.
Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","Data/company_logos_stock_analysis\Arcellx,_Inc._logo.svg",https://stockanalysis.com/stocks/aclx/,United States,2015,Biotechnology,Healthcare,130,Rami Elghandour,"800 Bridge Parkway
Redwood City, California 94065
United States",240 327 0603,arcellx.com,ACLX,NASDAQ,January - December,USD,0001786205,03940C100,US03940C1009,2836,"Feb 4, 2022",,47-2855917,$15.00,
Verona Pharma plc,"Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.
Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.",Data/company_logos_stock_analysis\Verona_Pharma_plc_logo.svg,https://stockanalysis.com/stocks/vrna/,United Kingdom,2005,Biotechnology,Healthcare,79,David Zaccardelli,"3 More London Riverside
London, SE1 2RE
United Kingdom",44 20 3283 4200,veronapharma.com,VRNA,NASDAQ,January - December,USD,0001657312,925050106,US9250501064,2834,"Apr 27, 2017",,,,
Prestige Consumer Healthcare Inc.,"Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal.
The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; Dramamine for motion sickness relief; enemas and other laxative products under the Fleet brand name; Gaviscon for upset stomach; cough drops under the Luden's brand; Monistat for yeast infections in women; Nix for lice and parasite treatments; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; TheraTears for dry eyes; nasal saline sprays and washes under the Fess brand name; and Hydralyte for oral rehydration.
It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels.
The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018.
Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.",Data/company_logos_stock_analysis\Prestige_Consumer_Healthcare_Inc._logo.svg,https://stockanalysis.com/stocks/pbh/,United States,1996,Drug Manufacturers - Specialty & Generic,Healthcare,570,Ronald Lombardi,"660 White Plains Road, Suite 250
Tarrytown, New York 10591
United States",914 524 6800,prestigebrands.com,PBH,NYSE,April - March,USD,0001295947,74112D101,US74112D1019,2834,"Feb 10, 2005",Common Stock,20-1297589,,
"Rhythm Pharmaceuticals, Inc.","Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.
Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","Data/company_logos_stock_analysis\Rhythm_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/rytm/,United States,2008,Biotechnology,Healthcare,226,David Meeker,"222 Berkeley Street, 12th Floor
Boston, Massachusetts 02116
United States",857 264 4280,rhythmtx.com,RYTM,NASDAQ,January - December,USD,0001649904,76243J105,US76243J1051,2834,"Oct 5, 2017",Common Stock,46-2159271,,
"Avidity Biosciences, Inc.","Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics.
The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial.
The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Avidity_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/rna/,United States,2012,Biotechnology,Healthcare,253,Sarah Boyce,"10578 Science Center Drive, Suite 125
San Diego, California 92121
United States",858 401 7900,aviditybiosciences.com,RNA,NASDAQ,January - December,USD,0001574111,05370A108,US05370A1088,2834,"Jun 12, 2020",Common Stock,,$18.00,
"Immunovant, Inc.","Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia.
Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","Data/company_logos_stock_analysis\Immunovant,_Inc._logo.svg",https://stockanalysis.com/stocks/imvt/,United States,,Biotechnology,Healthcare,207,Peter Salzmann,"320 West 37th Street, 6th Floor
New York, New York 10018
United States",(917) 580-3099,immunovant.com,IMVT,NASDAQ,April - March,USD,0001764013,45258J102,US45258J1025,2836,,,83-2771572,,
Biohaven Ltd.,"Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.
The company’s pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson’s disease, sclerosis, and amyloid-related imaging abnormalities.
It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.
In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin’s lymphoma.
It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022.
Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.",Data/company_logos_stock_analysis\Biohaven_Ltd._logo.svg,https://stockanalysis.com/stocks/bhvn/,United States,2013,Biotechnology,Healthcare,239,Vladimir Coric,"215 Church Street
New Haven, Connecticut 06510
United States",203 404 0410,biohaven.com,BHVN,NYSE,January - December,USD,0001935979,G11196105,VGG1110E1079,2834,"May 4, 2017",,,,
"Apellis Pharmaceuticals, Inc.","Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.
It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases.
The company was incorporated in 2009 and is based in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Apellis_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/apls/,United States,2009,Biotechnology,Healthcare,706,Cedric Francois,"100 Fifth Avenue
Waltham, Massachusetts 02451
United States",617 977 5700,apellis.com,APLS,NASDAQ,January - December,USD,0001492422,03753U106,US03753U1060,2834,"Nov 9, 2017",Common Stock,27-1537290,,
"PTC Therapeutics, Inc.","PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
The company distributes its products through third-party distributors. It has collaborations with F.
Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program.
PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.","Data/company_logos_stock_analysis\PTC_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ptct/,United States,1998,Biotechnology,Healthcare,"1,055",Matthew Klein,"100 Corporate Court
South Plainfield, New Jersey 07080
United States",908 222 7000,ptcbio.com,PTCT,NASDAQ,January - December,USD,0001070081,69366J200,US69366J2006,2834,"Jun 20, 2013",Common Stock,04-3416587,,
Perrigo Company plc,"Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products.
The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands.
It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies.
The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013.
Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.",Data/company_logos_stock_analysis\Perrigo_Company_plc_logo.svg,https://stockanalysis.com/stocks/prgo/,Ireland,1887,Drug Manufacturers - Specialty & Generic,Healthcare,"9,140",Patrick Lockwood-Taylor,"The Sharp Building, Hogan Place
Dublin, D02 TY74
Ireland",353 1 709 4000,perrigo.com,PRGO,NYSE,January - December,USD,0001585364,G97822103,IE00BGH1M568,2834,"Dec 16, 1991",,,,
CRISPR Therapeutics AG,"CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA.
The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.
It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.",Data/company_logos_stock_analysis\CRISPR_Therapeutics_AG_logo.svg,https://stockanalysis.com/stocks/crsp/,Switzerland,2013,Biotechnology,Healthcare,407,Samarth Kulkarni,"Baarerstrasse 14
Zug, 6300
Switzerland",41 41 561 32 77,crisprtx.com,CRSP,NASDAQ,January - December,USD,0001674416,H17182108,CH0334081137,2836,"Oct 19, 2016",,47-3173478,,
"SpringWorks Therapeutics, Inc.","SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas.
In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations.
The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib.
It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor.
The company was founded in 2017 and is headquartered in Stamford, Connecticut.","Data/company_logos_stock_analysis\SpringWorks_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/swtx/,United States,2017,Biotechnology,Healthcare,305,Saqib Islam,"100 Washington Boulevard
Stamford, Connecticut 06902
United States",203 883 9490,springworkstx.com,SWTX,NASDAQ,January - December,USD,0000813619,85205L107,US85205L1070,3081,"Sep 13, 2019",Common Stock,94-2551470,$18.00,
Merus N.V.,"Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers.
The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.",Data/company_logos_stock_analysis\Merus_N.V._logo.svg,https://stockanalysis.com/stocks/mrus/,Netherlands,2003,Biotechnology,Healthcare,229,Sven Lundberg,"Uppsalalaan 17, 3rd & 4th floor
Utrecht, 3584 CT
Netherlands",31 30 253 8800,merus.nl,MRUS,NASDAQ,January - December,USD,0001651311,N5749R100,NL0011606264,2834,"May 19, 2016",Common Stock,,,
Xenon Pharmaceuticals Inc.,"Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada.
Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.",Data/company_logos_stock_analysis\Xenon_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/xene/,Canada,1996,Biotechnology,Healthcare,259,Ian Mortimer,"3650 Gilmore Way, Suite 200
Burnaby, BC V5G 4W8
Canada",604 484 3300,xenon-pharma.com,XENE,NASDAQ,January - December,USD,0001582313,98420N105,CA98420N1050,2834,"Nov 5, 2014",,98-0661854,,
MoonLake Immunotherapeutics,"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.",Data/company_logos_stock_analysis\MoonLake_Immunotherapeutics_logo.svg,https://stockanalysis.com/stocks/mltx/,Switzerland,2021,Biotechnology,Healthcare,50,Jorge da Silva,"Dorfstrasse 29
Zug, 6300
Switzerland",41 415108022,moonlaketx.com,MLTX,NASDAQ,January - December,USD,0001821586,61559X104,KY61559X1045,2834,,,,,Class A Shares
Vericel Corporation,"Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.
The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Vericel_Corporation_logo.svg,https://stockanalysis.com/stocks/vcel/,United States,1989,Biotechnology,Healthcare,314,Dominick Colangelo,"64 Sidney Street
Cambridge, Massachusetts 02139
United States",617 588 5555,vcel.com,VCEL,NASDAQ,January - December,USD,0000887359,92346J108,US92346J1088,2836,"Feb 4, 1997",Common Stock,94-3096597,,
Bausch Health Companies Inc.,"Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally.
The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States.
The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.
Bausch Health Companies Inc. is headquartered in Laval, Canada.",Data/company_logos_stock_analysis\Bausch_Health_Companies_Inc._logo.svg,https://stockanalysis.com/stocks/bhc/,Canada,,Drug Manufacturers - Specialty & Generic,Healthcare,"20,270",Thomas Appio,"2150 St. ElzEar Boulevard West
Laval, QC H7L 4A8
Canada",514 744 6792,bauschhealth.com,BHC,NYSE,January - December,USD,0000885590,071734107,CA0717341071,2834,,,,,
ACADIA Pharmaceuticals Inc.,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS.
The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997.
ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.",Data/company_logos_stock_analysis\ACADIA_Pharmaceuticals_Inc._logo.svg,https://stockanalysis.com/stocks/acad/,United States,1993,Biotechnology,Healthcare,598,Catherine Owen Adams,"12830 El Camino Real, Suite 400
San Diego, California 92130
United States",858 558 2871,acadia.com,ACAD,NASDAQ,January - December,USD,0001070494,004225108,US0042251084,2834,"May 27, 2004",Common Stock,06-1376651,,
Zai Lab Limited,"Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions.
It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO.
The company was incorporated in 2013 and is headquartered in Shanghai, China.",Data/company_logos_stock_analysis\Zai_Lab_Limited_logo.svg,https://stockanalysis.com/stocks/zlab/,China,2013,Biotechnology,Healthcare,"2,175",Ying Du,"Jinchuang Plaza, Building 1, Fourth Floor
Shanghai, 201210
China",86 21 6163 2588,zailaboratory.com,ZLAB,NASDAQ,January - December,USD,0001704292,98887Q104,US98887Q1040,2834,"Sep 20, 2017",,,,
Denali Therapeutics Inc.,"Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States.
The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.
It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs.
The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.
Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",Data/company_logos_stock_analysis\Denali_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/dnli/,United States,2013,Biotechnology,Healthcare,445,Ryan Watts,"161 Oyster Point Boulevard
South San Francisco, California 94080
United States",650 866 8548,denalitherapeutics.com,DNLI,NASDAQ,January - December,USD,0001714899,24823R105,US24823R1059,2836,"Dec 8, 2017",Common Stock,46-3872213,,
"Janux Therapeutics, Inc.","Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates.
Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.","Data/company_logos_stock_analysis\Janux_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/janx/,United States,2017,Biotechnology,Healthcare,64,David Campbell,"10955 Vista Sorrento Parkway, Suite 200
San Diego, California 92130
United States",858 751 4493,januxrx.com,JANX,NASDAQ,January - December,USD,0001817713,47103J105,US47103J1051,2834,"Jun 11, 2021",Common Stock,82-2289112,$17.00,
"Amicus Therapeutics, Inc.","Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.","Data/company_logos_stock_analysis\Amicus_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/fold/,United States,2002,Biotechnology,Healthcare,517,Bradley Campbell,"47 Hulfish Street
Princeton, New Jersey 08542
United States",609 662 2000,amicusrx.com,FOLD,NASDAQ,January - December,USD,0001178879,03152W109,US03152W1099,2834,"May 31, 2007",Common Stock,20-0422823,,
NewAmsterdam Pharma Company N.V.,"NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.",Data/company_logos_stock_analysis\NewAmsterdam_Pharma_Company_N.V._logo.svg,https://stockanalysis.com/stocks/nams/,Netherlands,2019,Biotechnology,Healthcare,29,Michael Davidson,"Gooimeer 2-35
Naarden, 1411 DC
Netherlands",31 35 206 2971,newamsterdampharma.com,NAMS,NASDAQ,January - December,USD,0001936258,,NL00150012L7,2834,,,,,
"Kymera Therapeutics, Inc.","Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Kymera_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/kymr/,United States,2015,Biotechnology,Healthcare,187,Nello Mainolfi,"200 Arsenal Yards Boulevard, Suite 230
Watertown, Massachusetts 02472
United States",857 285 5300,kymeratx.com,KYMR,NASDAQ,January - December,USD,0001815442,501575104,US5015751044,2836,"Aug 21, 2020",Common Stock,81-2992166,$20.00,
HUTCHMED (China) Limited,"HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.
The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.
In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton’s tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms.
It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.
HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.",Data/company_logos_stock_analysis\HUTCHMED_(China)_Limited_logo.svg,https://stockanalysis.com/stocks/hcm/,Hong Kong,2000,Drug Manufacturers - Specialty & Generic,Healthcare,"1,988",Wei-Guo Su,"Cheung Kong Center, 48th floor
Hong Kong
Hong Kong",852 2121 8200,hutch-med.com,HCM,NASDAQ,January - December,USD,0001648257,44842L103,US44842L1035,2834,,,,,
"Catalyst Pharmaceuticals, Inc.","Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.
It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
The company was founded in 2002 and is based in Coral Gables, Florida.","Data/company_logos_stock_analysis\Catalyst_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/cprx/,United States,2002,Biotechnology,Healthcare,167,Richard John Daly,"355 Alhambra Circle, Suite 801
Coral Gables, Florida 33134
United States",305 420 3200,catalystpharma.com,CPRX,NASDAQ,January - December,USD,0001369568,14888U101,US14888U1016,2834,"Nov 8, 2006",Common Stock,,,
"Amneal Pharmaceuticals, Inc.","Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders.
This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson’s disease.
The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.
This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.
It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.
The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018.
Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.","Data/company_logos_stock_analysis\Amneal_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/amrx/,United States,2002,Drug Manufacturers - Specialty & Generic,Healthcare,"7,850",Chirag K. Patel,"400 Crossing Boulevard, 3rd Floor
Bridgewater, New Jersey 08807
United States",908 947 3120,amneal.com,AMRX,NASDAQ,January - December,USD,0001723128,03168L105,US03168L1052,2834,,,,,Class A Shares
"Protagonist Therapeutics, Inc.","Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.","Data/company_logos_stock_analysis\Protagonist_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ptgx/,United States,2006,Biotechnology,Healthcare,112,Dinesh Patel,"7707 Gateway Boulevard, Suite 140
Newark, California 94560-1160
United States",510 474 0170,protagonist-inc.com,PTGX,NASDAQ,January - December,USD,0001377121,74366E102,US74366E1029,2834,"Aug 11, 2016",Common Stock,98-0505495,,
"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B.
In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials.
Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial.
Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No.
3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.","Data/company_logos_stock_analysis\Arrowhead_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/arwr/,United States,2003,Biotechnology,Healthcare,609,Christopher Anzalone,"177 East Colorado Boulevard, Suite 700
Pasadena, California 91105
United States",626 304 3400,arrowheadpharma.com,ARWR,NASDAQ,October - September,USD,0000879407,04280A100,US04280A1007,2834,"Jun 16, 1993",Common Stock,46-0408024,,
"Vera Therapeutics, Inc.","Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections.
The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","Data/company_logos_stock_analysis\Vera_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/vera/,United States,2016,Biotechnology,Healthcare,51,Marshall Fordyce,"8000 Marina Boulevard, Suite 120
Brisbane, California 94005
United States",650 770 0077,veratx.com,VERA,NASDAQ,January - December,USD,0001831828,92337R101,US92337R1014,2834,"May 14, 2021",Common Stock,81-2744449,$11.00,Class A Shares
"Edgewise Therapeutics, Inc.","Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials.
In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.","Data/company_logos_stock_analysis\Edgewise_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/ewtx/,United States,2017,Biotechnology,Healthcare,88,Kevin Koch,"1715 38th Street
Boulder, Colorado 80301
United States",720 262 7002,edgewisetx.com,EWTX,NASDAQ,January - December,USD,0001710072,28036F105,US28036F1057,2834,"Mar 26, 2021",Common Stock,82-1725586,$16.00,
"Apogee Therapeutics, Inc.","Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.","Data/company_logos_stock_analysis\Apogee_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/apge/,United States,2022,Biotechnology,Healthcare,91,Michael Henderson,"221 Crescent Street, Building 17
Waltham, Massachusetts 02453
United States",650 394 5230,apogeetherapeutics.com,APGE,NASDAQ,January - December,USD,0001974640,03770N101,US03770N1019,2836,"Jul 14, 2023",,93-4958665,$17.00,
"Supernus Pharmaceuticals, Inc.","Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.
In addition, the company’s product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage.
It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.
Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.","Data/company_logos_stock_analysis\Supernus_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/supn/,United States,2005,Drug Manufacturers - Specialty & Generic,Healthcare,652,Jack Khattar,"9715 Key West Avenue
Rockville, Maryland 20850
United States",301 838 2500,supernus.com,SUPN,NASDAQ,January - December,USD,0001356576,868459108,US8684591089,2834,"May 1, 2012",Common Stock,,,
"IDEAYA Biosciences, Inc.","IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester.
IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.","Data/company_logos_stock_analysis\IDEAYA_Biosciences,_Inc._logo.svg",https://stockanalysis.com/stocks/idya/,United States,2015,Biotechnology,Healthcare,124,Yujiro Hata,"7000 Shoreline Court, Suite 350
South San Francisco, California 94080
United States",650 443 6209,ideayabio.com,IDYA,NASDAQ,January - December,USD,0001676725,45166A102,US45166A1025,2834,"May 23, 2019",Common Stock,47-4268251,$10.00,
Centessa Pharmaceuticals plc,"Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.",Data/company_logos_stock_analysis\Centessa_Pharmaceuticals_plc_logo.svg,https://stockanalysis.com/stocks/cnta/,United Kingdom,2020,Biotechnology,Healthcare,76,Saurabh Saha,"1 Ashley Road, 3rd Floor
Altrincham, WA14 2DT
United Kingdom",,centessa.com,CNTA,NASDAQ,January - December,USD,0001847903,152309100,US1523091007,2834,"May 28, 2021",,,$20.00,
Beam Therapeutics Inc.,"Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.",Data/company_logos_stock_analysis\Beam_Therapeutics_Inc._logo.svg,https://stockanalysis.com/stocks/beam/,United States,2017,Biotechnology,Healthcare,436,John Evans,"238 Main Street, 9th Floor
Cambridge, Massachusetts 02142-1016
United States",857 327 8775,beamtx.com,BEAM,NASDAQ,January - December,USD,0000789073,07373V105,US07373V1052,2080,"Feb 6, 2020",Common Stock,13-3295276,$17.00,
"CG Oncology, Inc.","CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer.
The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.
CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.
CG Oncology, Inc. was founded in 2010 and is based in Irvine, California.","Data/company_logos_stock_analysis\CG_Oncology,_Inc._logo.svg",https://stockanalysis.com/stocks/cgon/,United States,2010,Biotechnology,Healthcare,61,Arthur Kuan,"400 Spectrum Center Drive, Suite 2040
Irvine, California 92618
United States",949 409 3700,cgoncology.com,CGON,NASDAQ,January - December,USD,0001991792,,US1569441009,2836,"Jan 25, 2024",Common Stock,37-1611499,$19.00,
Ligand Pharmaceuticals Incorporated,"Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications.
The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.
Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.",Data/company_logos_stock_analysis\Ligand_Pharmaceuticals_Incorporated_logo.svg,https://stockanalysis.com/stocks/lgnd/,United States,1987,Biotechnology,Healthcare,58,Todd Davis,"555 Heritage Drive, Suite 200
Jupiter, Florida 33458
United States",858 550 7500,ligand.com,LGND,NASDAQ,January - December,USD,0000886163,53220K504,US53220K5048,2834,"Nov 18, 1992",Common Stock,77-0160744,,
"Tarsus Pharmaceuticals, Inc.","Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention.
Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.","Data/company_logos_stock_analysis\Tarsus_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/tars/,United States,2016,Biotechnology,Healthcare,244,Bobak Azamian,"15440 Laguna Canyon Road, Suite 160
Irvine, California 92618
United States",949 409 1801,tarsusrx.com,TARS,NASDAQ,January - December,USD,0001819790,87650L103,US87650L1035,2836,"Oct 16, 2020",Common Stock,81-4717861,$16.00,
"Recursion Pharmaceuticals, Inc.","Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","Data/company_logos_stock_analysis\Recursion_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/rxrx/,United States,2013,Biotechnology,Healthcare,500,Christopher Gibson,"41 South Rio Grande Street
Salt Lake City, Utah 84101
United States",385 269 0203,recursion.com,RXRX,NASDAQ,January - December,USD,0001601830,75629V104,US75629V1044,2836,"Apr 16, 2021",Common Stock,46-4099738,$18.00,Class A Shares
"Agios Pharmaceuticals, Inc.","Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","Data/company_logos_stock_analysis\Agios_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/agio/,United States,2007,Biotechnology,Healthcare,386,Brian Goff,"88 Sidney Street
Cambridge, Massachusetts 02139
United States",617 649 8600,agios.com,AGIO,NASDAQ,January - December,USD,0001439222,00847X104,US00847X1046,2834,"Jul 24, 2013",Common Stock,,,
"Harmony Biosciences Holdings, Inc.","Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.","Data/company_logos_stock_analysis\Harmony_Biosciences_Holdings,_Inc._logo.svg",https://stockanalysis.com/stocks/hrmy/,United States,2017,Biotechnology,Healthcare,246,Jeffrey Dayno,"630 West Germantown Pike, Suite 215
Plymouth Meeting, Pennsylvania 19462
United States",484 539 9800,harmonybiosciences.com,HRMY,NASDAQ,January - December,USD,0001802665,413197104,US4131971040,2834,"Aug 19, 2020",Common Stock,82-2279923,$24.00,
Mesoblast Limited,"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.
It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.
The company was incorporated in 2004 and is headquartered in Melbourne, Australia.",Data/company_logos_stock_analysis\Mesoblast_Limited_logo.svg,https://stockanalysis.com/stocks/meso/,Australia,2004,Biotechnology,Healthcare,73,Silviu Itescu,"55 Collins Street, Level 38
Melbourne, VIC 3000
Australia",61 3 9639 6036,mesoblast.com,MESO,NASDAQ,July - June,USD,0001345099,590717104,US5907174016,2836,,,,,
"Iovance Biotherapeutics, Inc.","Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.
The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H.
Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.
The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.
Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.","Data/company_logos_stock_analysis\Iovance_Biotherapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/iova/,United States,2007,Biotechnology,Healthcare,557,Frederick Vogt,"825 Industrial Road, Suite 400
San Carlos, California 94070
United States",650 260 7120,iovance.com,IOVA,NASDAQ,January - December,USD,0001425205,462260100,US4622601007,2836,,,75-3254381,,
"Mirum Pharmaceuticals, Inc.","Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases.
The company was incorporated in 2018 and is headquartered in Foster City, California.","Data/company_logos_stock_analysis\Mirum_Pharmaceuticals,_Inc._logo.svg",https://stockanalysis.com/stocks/mirm/,United States,2018,Biotechnology,Healthcare,264,Christopher Peetz,"950 Tower Lane, Suite 1050
Foster City, California 94404
United States",650 667 4085,mirumpharma.com,MIRM,NASDAQ,January - December,USD,0001759425,604749101,US6047491013,2834,"Jul 18, 2019",Common Stock,83-1281555,$15.00,
Geron Corporation,"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.",Data/company_logos_stock_analysis\Geron_Corporation_logo.svg,https://stockanalysis.com/stocks/gern/,United States,1990,Biotechnology,Healthcare,141,John Scarlett,"919 East Hillsdale Boulevard, Suite 250
Foster City, California 94404
United States",650 473 7700,geron.com,GERN,NASDAQ,January - December,USD,0000886744,374163103,US3741631036,2834,"Jun 30, 1996",Common Stock,75-2287752,,
"Disc Medicine, Inc.","Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.
The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases.
Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.","Data/company_logos_stock_analysis\Disc_Medicine,_Inc._logo.svg",https://stockanalysis.com/stocks/iron/,United States,2017,Biotechnology,Healthcare,74,John Quisel,"321 Arsenal Street, Suite 101
Watertown, Massachusetts 02472
United States",617 674 9274,discmedicine.com,IRON,NASDAQ,January - December,USD,0001816736,,US2546041011,2834,,Common Stock,85-1613057,,
"Soleno Therapeutics, Inc.","Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.","Data/company_logos_stock_analysis\Soleno_Therapeutics,_Inc._logo.svg",https://stockanalysis.com/stocks/slno/,United States,1999,Biotechnology,Healthcare,33,Anish Bhatnagar,"203 Redwood Shores Parkway, Suite 500
Redwood City, California 94065
United States",650 213 8444,soleno.life,SLNO,NASDAQ,January - December,USD,0001484565,834203200,US8342033094,3845,"Nov 13, 2014",Common Stock,77-0523891,,
